COMP <GO>
CTOR vs SER // EV/EBITDA & P/E VALUATION
Citius Oncology Inc. (NASDAQ) VS. Serina Therapeutics Inc. (NYSE) • 15-METRIC TALLY: CTOR 1
— SER 2
■ METRIC PARITY
LAST: $0.53 (-8.20%) • MKT CAP: $49.2M
valuation
—
LAST: $1.89 (+15.24%) • MKT CAP: $48.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTOR VS. SER)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CTOR | SER | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -11.16% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 132.10% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 3/9 | -2.00 | SER | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 29.1 | 52.3 | -23.27 | SER | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $49.2M | $48.0M | $1.2M | CTOR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CTOR REV | SER REV | CTOR GROSS % | SER GROSS % | CTOR FCF | SER FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $130.0K | — | — | -$5.5M | -$18.0M |
| FY 2024 | $0 | $56.0K | — | — | $126.4K | -$17.2M |
| FY 2023 | $0 | $3.2M | — | — | -$601.3K | -$2.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTOR // BETA —
SER // BETA —